Martin Mackay’s rare disease startup gets $145 million as it enters the clinic

Two years ago, Martin Mackay took a couple of fellow exiles from Alexion’s 2017 culling and, after 3 decades in Big Pharma and big biotech, struck out on his own, with a vague vision that was as small as it was broad. They called it Rallybio and it was going to focus on rare diseases — they just didn’t say which of the thousands of those rare diseases that would be.